In this study we show that CD155 immune checkpoint is expressed in all MB subgroups and that interfering with the CD155/TIGIT axis using anti-TIGIT Tiragolumab potentiates MB tumor cell killing by NK cells (Figs. 1 and 2). Here, TIGIT is linked to neoplasm.